Switch theme
Sign up to access all valuation multiples
Dr. Reddy’s is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy’s also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy’s has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy’s also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.
1984
27.0K+
LTM Revenue $3.9B
LTM EBITDA $1.0B
$12.0B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Dr. Reddy's Laboratories has a last 12-month revenue (LTM) of $3.9B and a last 12-month EBITDA of $1.0B.
In the most recent fiscal year, Dr. Reddy's Laboratories achieved revenue of $3.3B and an EBITDA of $1.0B.
Dr. Reddy's Laboratories expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Dr. Reddy's Laboratories valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $3.9B | XXX | $3.3B | XXX | XXX | XXX |
| Gross Profit | $2.3B | XXX | $1.9B | XXX | XXX | XXX |
| Gross Margin | 60% | XXX | 59% | XXX | XXX | XXX |
| EBITDA | $1.0B | XXX | $1.0B | XXX | XXX | XXX |
| EBITDA Margin | 27% | XXX | 32% | XXX | XXX | XXX |
| EBIT | $835M | XXX | $765M | XXX | XXX | XXX |
| EBIT Margin | 22% | XXX | 23% | XXX | XXX | XXX |
| Net Profit | $664M | XXX | $652M | XXX | XXX | XXX |
| Net Margin | 17% | XXX | 20% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $110M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Dr. Reddy's Laboratories's stock price is INR 1252 (or $15).
Dr. Reddy's Laboratories has current market cap of INR 1.04T (or $12.2B), and EV of INR 1.03T (or $12.0B).
See Dr. Reddy's Laboratories trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $12.0B | $12.2B | XXX | XXX | XXX | XXX | $0.79 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Dr. Reddy's Laboratories has market cap of $12.2B and EV of $12.0B.
Dr. Reddy's Laboratories's trades at 3.8x EV/Revenue multiple, and 12.1x EV/EBITDA.
Equity research analysts estimate Dr. Reddy's Laboratories's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Dr. Reddy's Laboratories has a P/E ratio of 18.4x.
See valuation multiples for Dr. Reddy's Laboratories and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $12.2B | XXX | $12.2B | XXX | XXX | XXX |
| EV (current) | $12.0B | XXX | $12.0B | XXX | XXX | XXX |
| EV/Revenue | 3.1x | XXX | 3.8x | XXX | XXX | XXX |
| EV/EBITDA | 11.7x | XXX | 12.1x | XXX | XXX | XXX |
| EV/EBIT | 14.4x | XXX | 16.1x | XXX | XXX | XXX |
| EV/Gross Profit | 5.2x | XXX | n/a | XXX | XXX | XXX |
| P/E | 18.4x | XXX | 19.6x | XXX | XXX | XXX |
| EV/FCF | -41.4x | XXX | 43.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialDr. Reddy's Laboratories's last 12 month revenue growth is 7%
Dr. Reddy's Laboratories's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $43K for the same period.
Dr. Reddy's Laboratories's rule of 40 is 38% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Dr. Reddy's Laboratories's rule of X is 44% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Dr. Reddy's Laboratories and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 7% | XXX | 14% | XXX | XXX | XXX |
| EBITDA Margin | 27% | XXX | 31% | XXX | XXX | XXX |
| EBITDA Growth | 2% | XXX | -2% | XXX | XXX | XXX |
| Rule of 40 | 38% | XXX | 38% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 44% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $43K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 8% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 35% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Dr. Reddy's Laboratories acquired XXX companies to date.
Last acquisition by Dr. Reddy's Laboratories was XXXXXXXX, XXXXX XXXXX XXXXXX . Dr. Reddy's Laboratories acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Dr. Reddy's Laboratories founded? | Dr. Reddy's Laboratories was founded in 1984. |
| Where is Dr. Reddy's Laboratories headquartered? | Dr. Reddy's Laboratories is headquartered in India. |
| How many employees does Dr. Reddy's Laboratories have? | As of today, Dr. Reddy's Laboratories has 27.0K+ employees. |
| Who is the CEO of Dr. Reddy's Laboratories? | Dr. Reddy's Laboratories's CEO is Mr. M. V. Ramana. |
| Is Dr. Reddy's Laboratories publicy listed? | Yes, Dr. Reddy's Laboratories is a public company listed on BOM. |
| What is the stock symbol of Dr. Reddy's Laboratories? | Dr. Reddy's Laboratories trades under 500124 ticker. |
| When did Dr. Reddy's Laboratories go public? | Dr. Reddy's Laboratories went public in 1992. |
| Who are competitors of Dr. Reddy's Laboratories? | Similar companies to Dr. Reddy's Laboratories include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Dr. Reddy's Laboratories? | Dr. Reddy's Laboratories's current market cap is $12.2B |
| What is the current revenue of Dr. Reddy's Laboratories? | Dr. Reddy's Laboratories's last 12 months revenue is $3.9B. |
| What is the current revenue growth of Dr. Reddy's Laboratories? | Dr. Reddy's Laboratories revenue growth (NTM/LTM) is 7%. |
| What is the current EV/Revenue multiple of Dr. Reddy's Laboratories? | Current revenue multiple of Dr. Reddy's Laboratories is 3.1x. |
| Is Dr. Reddy's Laboratories profitable? | Yes, Dr. Reddy's Laboratories is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Dr. Reddy's Laboratories? | Dr. Reddy's Laboratories's last 12 months EBITDA is $1.0B. |
| What is Dr. Reddy's Laboratories's EBITDA margin? | Dr. Reddy's Laboratories's last 12 months EBITDA margin is 27%. |
| What is the current EV/EBITDA multiple of Dr. Reddy's Laboratories? | Current EBITDA multiple of Dr. Reddy's Laboratories is 11.7x. |
| What is the current FCF of Dr. Reddy's Laboratories? | Dr. Reddy's Laboratories's last 12 months FCF is -$290M. |
| What is Dr. Reddy's Laboratories's FCF margin? | Dr. Reddy's Laboratories's last 12 months FCF margin is -8%. |
| What is the current EV/FCF multiple of Dr. Reddy's Laboratories? | Current FCF multiple of Dr. Reddy's Laboratories is -41.4x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
